A new study presented at the Society for Neuro-Oncology conference last week reported that cancer vaccine, rindopepimut, has been shown to reduce the risk of death for glioblastoma (GBM) patients by 47 percent.
The EF-14 trial achieved statistically significant extension of both progression-free survival and overall survival in newly diagnosed glioblastoma with a 50% increase in the number of patients alive two-years after starting treatment when treated with TTFields in combination with temozolomide as compared to temozolomide alone.
A new study reveals that while brain metastases share some genetic characteristics with their primary tumors, they also carry unique genetic mutations. The study also report that brain metastases may continue to evolve after leaving the primary tumor site.
According to a new study published in PLOS ONE, using blood samples collected, over can average of 15 years before brain tumor diagnosis to analyze relationships between 12 allergy-related proteins, researchers at Ohio State University looked at how those relationships were different between people later diagnosed with brain tumors and cancer-free groups.